Article
Multidisciplinary Sciences
D. G. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. T. Martin, J. Kmiecik, D. Bobbala, A. S. Aitken, C. T. de Souza, K. B. Stephenson, B. D. Lichty, R. C. Auer, D. F. Stojdl, J. C. Bell, M-C Bourgeois-Daigneault
Summary: Vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as antigen-engineered oncolytic viruses, providing a potential alternative for personalized anti-cancer vaccines targeting patient-specific mutations.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Annette Runge, Melissa Mayr, Theresa Schwaiger, Susanne Sprung, Paolo Chetta, Timo Gottfried, Jozsef Dudas, Maria C. Greier, Marlies C. Glatz, Johannes Haybaeck, Knut Elbers, Herbert Riechelmann, Patrik Erlmann, Monika Petersson
Summary: The etiology and architecture of head and neck cancer are diverse and complex, making it difficult to predict patient responses to specific cancer immunotherapy or combination treatment. To bridge this gap, researchers have developed a patient-derived HNSCC (head and neck squamous cell carcinoma) slice culturing system. This system preserves the heterogeneous contexture of the human tumor ecosystem and functional immune cell compartment, allowing for assessment of immunomodulatory effects and oncolytic virus action.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Yuguo Zhang, Bolni Marius Nagalo
Summary: This article explores the use of vesicular stomatitis virus (VSV) as an immunovirotherapy in human cancers and discusses future perspectives and research areas to improve VSV-based oncotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jingshu Xiao, Jiaming Liang, Junjie Fan, Panpan Hou, Xiaodong Li, Haipeng Zhang, Kai Li, Lang Bu, Ping Li, Miao He, Yongheng Zhong, Liping Guo, Penghui Jia, Qiaoqiao Xiao, Junyu Wu, Hong Peng, Chunmei Li, Fan Xing, Deyin Guo
Summary: This study presents a promising strategy for the treatment of aggressive glioblastoma (GBM) by combining CDK4/6 inhibitors with oncolytic viruses (OV). CDK4/6 inhibition enhances the efficacy of OV by promoting autophagic degradation of MAVS, impairing antiviral responses, and amplifying oncolysis. Furthermore, CDK4/6 inhibitors and OV synergistically induce immuno-genic cell death and boost antitumor immunity, inhibiting tumor growth and prolonging survival in GBM models.
Article
Oncology
Lisa Pipperger, Lydia Riepler, Janine Kimpel, Anita Siller, Patrizia Stoitzner, Zoltan Banki, Dorothee von Laer
Summary: This study examined the interaction of oncolytic viruses with dendritic cells in different species and subsets, showing varied infection, activation, and cytokine production patterns. Matured dendritic cells were less susceptible to VSV-GP infection, while VSV-dM51-GP induced maturation and inflammatory cytokine release. Different dendritic cell types exhibited distinct responses to VSV and VSV-GP variants, highlighting the importance of considering these differences in immunological mechanisms of oncolytic virotherapy.
Article
Multidisciplinary Sciences
Stephanie L. Foster, Courtney Woolsey, Viktoriya Borisevich, Krystle N. Agans, Abhishek N. Prasad, Daniel J. Deer, Joan B. Geisbert, Natalie S. Dobias, Karla A. Fenton, Robert W. Cross, Thomas W. Geisbert
Summary: Nipah virus is an emerging highly lethal zoonotic disease that can be transmitted via respiratory droplets. A study has shown that a recombinant vesicular stomatitis virus-based vaccine can rapidly protect monkeys from lethal Nipah virus infection.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Tomohiko Sakuda, Tadahiko Kubo, Muhammad Phetrus Johan, Taisuke Furuta, Takemasa Sakaguchi, Nobuo Adachi
Summary: This study aimed to evaluate the oncolytic effect of VSV-miRNA on osteosarcoma cells in vivo. The results showed that rVSV-miR143 had a slightly synergistic antitumor effect, significantly reducing primary tumor volume. However, there was no significant difference in the impact on metastatic lesions and survival rate, whether administered through intratumoral or intravenous injection.
ANTICANCER RESEARCH
(2023)
Article
Biochemical Research Methods
Darshak Kartikey Bhatt, Thijs Janzen, Toos Daemen, Franz Weissing
Summary: Oncolytic virotherapy is a promising cancer treatment method that utilizes viruses to target, infect, and eliminate cancer cells. However, the presence of virus-resistant tumor cells often reduces its effectiveness. This study developed a cell-based model to explore the impact of viral infection on the dynamics of infection-sensitive and infection-resistant cells in tumor tissue and predict treatment efficacy. The model revealed that therapeutic outcomes are influenced by the death rate of infected cells, with rapid virus clearance leading to cancer persistence. Furthermore, the model identified three causes of therapy failure: rapid virus clearance, rapid selection of resistant cancer cells, and low viral spread due to infection-resistant healthy cells. The model suggests that improving therapeutic efficacy can be achieved by sensitizing healthy stromal cells to infection.
PLOS COMPUTATIONAL BIOLOGY
(2022)
Article
Immunology
Wenjun Zhu, Guodong Liu, Wenguang Cao, Shihua He, Anders Leung, Ute Stroher, Michael J. Fairchild, Rick Nichols, Joseph Crowell, Joan Fusco, Logan Banadyga
Summary: This study confirms the protective efficacy of a cloned rVSV candidate vaccine against MARV and highlights the potential predictive value of the guinea pig model in evaluating MARV countermeasures.
Review
Oncology
Molly C. Holbrook, Dakota W. Goad, Valery Z. Grdzelishvili
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis and a dismal survival rate, expected to become the second leading cause of cancer-related deaths in the United States. Oncolytic virus (OV) is an anticancer approach that utilizes replication-competent viruses to preferentially infect and kill tumor cells. Vesicular stomatitis virus (VSV), one such OV, is already in several phase I clinical trials against different malignancies. VSV-based recombinant viruses are effective OVs against a majority of tested PDAC cell lines. However, some PDAC cell lines are resistant to VSV. Mechanisms such as upregulated type I IFN signaling and inefficient viral attachment play a role in this resistance, but alternative approaches like combining VSV with JAK1/2 inhibitors have shown promise in overcoming this resistance.
Article
Multidisciplinary Sciences
Jingyuan Cong, Xiaoying Feng, Huiling Kang, Wangjun Fu, Lei Wang, Chenlong Wang, Xuemei Li, Yutao Chen, Zihe Rao
Summary: This study investigates the structure-function relationship of the L-P complex of Newcastle disease virus (NDV) using cryo-EM and enzymatic assays. The research reveals distinct conformations and interactions between L and P proteins, advancing our understanding of Paramyxoviridae RNA synthesis and providing potential therapeutic targets.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Saskia V. Vijver, Sarah Danklmaier, Lisa Pipperger, Raphael Gronauer, Gabriel Floriani, Hubert Hackl, Krishna Das, Guido Wollmann
Summary: This study aimed to identify the anti-viral T cells raised by VSV-GP virotherapy in C57BL/6J mice using a multi-level adapted bioinformatics approach. The top-ranked viral epitopes triggering IFN-gamma secretion due to T cell activation were identified and validated. Overall, this identification of VSV-GP T cell epitopes enables comprehensive monitoring of anti-viral T cell responses and supports the development of novel VSV-GP variants.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Laura Evgin, Tim Kottke, Jason Tonne, Jill Thompson, Amanda L. Huff, Jacob van Vloten, Madelyn Moore, Josefine Michael, Christopher Driscoll, Jose Pulido, Eric Swanson, Richard Kennedy, Matt Coffey, Houra Loghmani, Luis Sanchez-Perez, Gloria Olivier, Kevin Harrington, Hardev Pandha, Alan Melcher, Rosa Maria Diaz, Richard G. Vile
Summary: Combining oncolytic viruses (OVs) and CAR T cell therapy can enhance the efficacy of CAR T cells in the solid tumor microenvironment. Stimulation of the native T cell receptor by viral epitopes can enhance CAR T cell proliferation and antitumor function, leading to prolonged survival.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Virology
Qiang Hu, Yuhang Zhang, Jiafu Jiang, Aihua Zheng
Summary: A study found that two spontaneous mutations, M749T/C617R, in the Gc glycoprotein of a recombinant vesicular stomatitis virus-based vaccine candidate for SFTSV significantly increased the vaccine's titer. These mutations enhanced glycoprotein traffic to the plasma membrane, facilitating virus assembly, without affecting the vaccine's broad-spectrum immunogenicity. This finding could contribute to the future development of rVSV-SFTSV as an effective vaccine.
Article
Immunology
Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad Mire, Natalia Kuzmina, Noor Shaik, Sivakumar Periasamy, Matthew A. Hyde, Julie M. Williams, Pei-Yong Shi, Matthias J. Schnell, Alexander Bukreyev
Summary: The study developed a SARS-CoV-2 ConVac vaccine which, through animal experiments, showed that a single dose of the vaccine could rapidly control viral replication after disease challenge, protecting animals from weight loss and lung virus replication, with some inflammation still detected.
Article
Biotechnology & Applied Microbiology
Susanna C. Concilio, Lukkana Suksanpaisan, Linh Pham, Kah-Whye Peng, Stephen J. Russell
Summary: The sodium iodide symporter (NIS) is commonly used as a reporter gene, but faces limitations due to background signals. By comparing the transport properties of NIS from different species, it was found that the NIS from minke whale may be a superior candidate for reporter gene applications.
Article
Hematology
Maria Eleni Drosou, Lisa E. Vaughan, Eli Muchtar, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Ronald S. Go, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Prashant Kapoor, Taxiarchis Kourelis, Shaji Kumar, Robert A. Kyle, Martha Q. Lacy, Yi Lin, Camden L. Lopez, John A. Lust, S. Vincent Rajkumar, Stephen J. Russell, Surbhi Sidana, Mustaqeem A. Siddiqui, M. Hasib Sidiqi, Rahma Warsame, Nelson Leung
Summary: Three sets of criteria (ISA, Palladini, and Kastritis) were evaluated for predicting renal survival in AL amyloidosis patients. Palladini and Kastritis models showed differing abilities to predict end-stage renal disease risk, with Palladini being more predictive for stage II patients and Kastritis for responders at 3 months.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Eli Muchtar, Morie A. Gertz, Shaji K. Kumar, Martha Q. Lacy, Nelson Leung, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Ronald S. Go, Prashant Kapoor, Wilson Gonsalves, Taxiarchis V. Kourelis, Rahma Warsame, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Stephen Russell, John A. Lust, Mustaqueem Siddiqui, S. Vincent Rajkumar, Robert A. Kyle, Angela Dispenzieri
Summary: This study found that 17.5% of AL amyloidosis patients achieved delayed CR without further therapy after initially achieving VGPR. Patients with delayed CR had similar organ response rates to those with CR at the end of therapy, and higher PFS/OS compared to patients with CR or VGPR by the end of therapy.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Article
Clinical Neurology
David Adams, Michael Polydefkis, Alejandra Gonzalez-Duarte, Jonas Wixner, Arnt Kristen, Hartmut H. Schmidt, John L. Berk, Ines Asuncion Losada Lopez, Angela Dispenzieri, Dianna Quan, Isabel M. Conceicao, Michel S. Slama, Julian D. Gillmore, Theodoros Kyriakides, Senda Ajroud-Driss, Marcia Waddington-Cruz, Michelle M. Mezei, Violaine Plante-Bordeneuve, Shahram Attarian, Elizabeth Mauricio, Thomas H. Brannagan, Mitsuharu Ueda, Emre Aldinc, Jing Jing Wang, Matthew T. White, John Vest, Erhan Berber, Marianne T. Sweetser, Teresa Coelho
Summary: Hereditary transthyretin-mediated amyloidosis is a rare genetic disease caused by mutations in the TTR gene. Long-term treatment with patisiran, an RNA interference therapeutic, showed sustained efficacy and acceptable safety profile in patients with this condition, as demonstrated in a 12-month interim analysis of a global open-label extension study.
Article
Medicine, General & Internal
Eli Muchtar, Angela Dispenzieri, Morie A. Gertz, Shaji K. Kumar, Francis K. Buadi, Nelson Leung, Martha Q. Lacy, David Dingli, Sikander Ailawadhi, P. Leif Bergsagel, Rafael Fonseca, Suzanne R. Hayman, Prashant Kapoor, Martha Grogan, Omar F. Abou Ezzeddine, Julie L. Rosenthal, Michelle Mauermann, Mustaqueem Siddiqui, Wilson Gonsalves, Taxiarchis Kourelis, Jeremy T. Larsen, Craig B. Reeder, Rahma Warsame, Ronald S. Go, David L. Murray, Ellen D. McPhail, Surendra Dasari, Dragan Jevremovic, Robert A. Kyle, Yi Lin, John A. Lust, Stephen J. Russell, Yi Lisa Hwa, Amie L. Fonder, Miriam A. Hobbs, S. Vincent Rajkumar, Vivek Roy, Taimur Sher
Summary: AL amyloidosis is a clonal plasma cell disorder that can lead to organ failure. Early recognition, anti-plasma cell therapy, and supportive care are important for improving patient survival.
MAYO CLINIC PROCEEDINGS
(2021)
Review
Microbiology
Velia Penza, Stephen J. Russell, Autumn J. Schulze
Summary: The long polyC tracts in picornaviruses play a crucial role in viral pathogenesis, impacting replication, virulence, and immune cell targeting. These tracts have been successfully used in vaccine strategies and have potential applications in oncolytic virotherapy against cancer.
Article
Microbiology
Rianna Vandergaast, Timothy Carey, Samantha Reiter, Chase Lathrum, Patrycja Lech, Clement Gnanadurai, Michelle Haselton, Jason Buehler, Riya Narjari, Luke Schnebeck, Anne Roesler, Kara Sevola, Lukkana Suksanpaisan, Alice Bexon, Shruthi Naik, Bethany Brunton, Scott C. Weaver, Grace Rafael, Sheryl Tran, Alina Baum, Christos A. Kyratsous, Kah Whye Peng, Stephen J. Russell
Summary: This study describes the development and validation of IMMUNO-COV v2.0, a scalable clinical assay for measuring SARS-CoV-2-neutralizing antibody titers. The assay has been comprehensively validated and is suitable for clinical use in human serum and plasma, providing valuable insights into the levels of neutralizing antibodies and vaccine-induced immunity against SARS-CoV-2.
Article
Biotechnology & Applied Microbiology
Karol M. Budzik, Rebecca A. Nace, Yasuhiro Ikeda, Stephen J. Russell
Summary: Foamy Viruses are retroviruses that can persist unintegrated in quiescent cells until cell division occurs, making them potential candidates for targeting slowly dividing human tumor cells. Studies have shown that oncolytic Foamy Virus can efficiently carry foreign transgenes and maintain genetic stability in vivo, suggesting it is a promising gene delivery platform.
CANCER GENE THERAPY
(2022)
Article
Oncology
Moritz Binder, Bharat Nandakumar, S. Vincent Rajkumar, Prashant Kapoor, Francis K. Buadi, David Dingli, Martha Q. Lacy, Morie A. Gertz, Suzanne R. Hayman, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis Kourelis, Wilson Gonsalves, Stephen Russell, Yi Lin, Mustaqeem Siddiqui, Robert A. Kyle, Angela Dispenzieri, Shaji K. Kumar
Summary: Recent advancements in disease biology, drug development, and supportive care have led to improved outcomes in multiple myeloma patients. However, disparities exist in mortality trends among patient populations, with older patients and those with unfavorable disease characteristics experiencing higher excess mortality. Efforts should be made to develop safe and effective therapies for these vulnerable patients and to ensure timely access to specialized care in the community.
Article
Immunology
Kah-Whye Peng, Timothy Carey, Patrycja Lech, Rianna Vandergaast, Miguel A. Munoz-Alia, Nandakumar Packiriswamy, Clement Gnanadurai, Karina Krotova, Mulu Tesfay, Christopher Ziegler, Michelle Haselton, Kara Sevola, Chase Lathrum, Samantha Reiter, Riya Narjari, Baskar Balakrishnan, Lukkana Suksanpaisan, Toshie Sakuma, Jordan Recker, Lianwen Zhang, Scott Waniger, Luke Russell, Christopher D. Petro, Christos A. Kyratsous, Alina Baum, Jody L. Janecek, Rachael M. Lee, Sabarinathan Ramachandran, Melanie L. Graham, Stephen J. Russell
Summary: By using G protein trans-complementation, researchers have developed an orally active vaccine called VSV-SARS2(+G) that can significantly boost SARS-CoV-2 immunity in both virus-naive and vaccine-primed macaques, resulting in higher neutralizing antibody titers.
Article
Oncology
Yogesh R. Suryawanshi, Rebecca A. Nace, Stephen J. Russell, Autumn J. Schulze
Summary: The dual microRNA-detargeted oncolytic Mengovirus vMC(24)NC showed high efficacy and safety in an immunocompetent mouse model of plasmacytoma, while an attenuated Mengovirus vMC(24)Delta L, with a virulence gene deletion, induced significant toxicity in an immunodeficient xenograft mouse model of human glioblastoma. The microRNA-detargeted vMC(24)NC demonstrated excellent efficacy against U87-MG subcutaneous xenografts with improved overall survival, making it an ideal candidate for clinical development against certain cancers in both immunocompetent and immunodeficient hosts.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Hematology
Joselle Cook, Kah-Whye Peng, Thomas E. Witzig, Stephen M. Broski, Jose C. Villasboas, Jonas Paludo, Mrinal Patnaik, Vincent Rajkumar, Angela Dispenzieri, Nelson Leung, Francis Buadi, Nora Bennani, Stephen M. Ansell, Lianwen Zhang, Nandakumar Packiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda Ginos, Amylou C. Dueck, Susan Geyer, Morie A. Gertz, Rahma Warsame, Ronald S. Go, Suzanne R. Hayman, David Dingli, Shaji Kumar, Leif Bergsagel, Javier L. Munoz, Wilson Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Prashant Kapoor, Robert A. Kyle, Yi Lin, Mustaqeem Siddiqui, Amie Fonder, Miriam Hobbs, Lisa Hwa, Shruthi Naik, Stephen J. Russell, Martha Q. Lacy
Summary: This study investigated the safety and efficacy of intravenous oncolytic virotherapy in patients with relapsed/refractory hematologic malignancies. The results showed that VSV-IFN beta-NIS had significant therapeutic effects in patients with TCL, possibly through a combination of oncolytic tumor destruction and immune response.
Article
Endocrinology & Metabolism
Eli Muchtar, Matthew T. Drake, Nelson Leung, Angela Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Stephen Russell, Ronald S. Go, Moritz Binder, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar, Morie A. Gertz
Summary: The study found that vitamin D deficiency is common in AL amyloidosis patients, particularly among those with heavy proteinuria. Severe 25(OH)D deficiency at diagnosis predicts progression to end-stage renal disease.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Velia Penza, Justin W. Maroun, Rebecca A. Nace, Autumn J. Schulze, Stephen J. Russell
Summary: An improved version of Mengovirus has been developed as a potential treatment for cancer, showing reduced side effects on the nervous system and heart muscle. By modifying the virus's genes, it can stably retain its therapeutic effects and target specific areas without causing harm to the host.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Article
Cell Biology
Miguel Angel Munoz-Alia, Rebecca A. Nace, Lianwen Zhang, Stephen J. Russell
Summary: This study demonstrates that the evolution of measles virus is severely constrained by the existence of multiple co-dominant antigenic sites on the H glycoprotein, some of which are critical for binding to pathogenicity receptors. Protective neutralizing antibodies targeting co-dominant epitopes on the F glycoprotein have been identified in serum. Mutant measles viruses retaining even one co-dominant antigenic site are unlikely to escape serum neutralization in vaccinated individuals.
CELL REPORTS MEDICINE
(2021)
